Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company’s lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Metrics to compare | ANNX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipANNXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.8x | −4.5x | −0.5x | |
PEG Ratio | −0.12 | 0.02 | 0.00 | |
Price / Book | 1.3x | 3.2x | 2.6x | |
Price / LTM Sales | - | 8.8x | 3.1x | |
Upside (Analyst Target) | 297.1% | 140.4% | 45.7% | |
Fair Value Upside | Unlock | 10.6% | 5.7% | Unlock |